Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno ...

Dr. Reid brings 30 years of experience in building biotech companies based on innovative scientific platforms and shaping ...

Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Friday reported second-quarter earnings of $1.39 billion.

TARRYTOWN, N.Y. (AP) — TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. (REGN) on Friday reported second-quarter earnings of $1.39 billion.

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

Michael Burry's Scion Asset Management ended the first quarter more bullish on companies across different sectors and ...

"Manufacturing issues at Novo facility disrupt Regeneron drug review" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

TARRYTOWN, N.Y., July 23, 2025 /PRNewswire/ -- The STEM Leadership Center is excited to announce the teachers selected and school districts represented in Cohort 12 of the Regeneron STEM Teaching ...

Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. Regeneron missed analysts’ revenue expectations by 6.1% ...